Matching articles for "Xofluza"
Issue 1740 · October 27, 2025 Free
Antiviral Drugs for Seasonal Influenza for 2025-2026

Influenza is generally a self-limited illness, but complications including pneumonia, respiratory failure, and death can occur, especially in persons at increased risk (see Table 1).

Med Lett Drugs Ther. 2025 Oct 27; 67(1740):169-74 doi:10.58347/tml.2025.1740a
Influenza is generally a self-limited illness, but complications including pneumonia, respiratory failure, and death can occur, especially in persons at increased risk (see Table 1).
Issue 1740 · October 27, 2025 Free
Comparison Table: Antiviral Drugs for Seasonal Influenza for 2025-2026 (online only)

View the Comparison Table: Antiviral Drugs for Seasonal Influenza for 2025-2026

Med Lett Drugs Ther. 2025 Oct 27; 67(1740):e178-80 doi:10.58347/tml.2025.1740d
View the Comparison Table: Antiviral Drugs for Seasonal Influenza for 2025-2026
Issue 1738 · September 29, 2025 Free
Influenza Vaccines for 2025-2026

Annual vaccination against influenza A and B viruses is recommended in the US for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2025-2026 season are listed…

Med Lett Drugs Ther. 2025 Sep 29; 67(1738):153-8 doi:10.58347/tml.2025.1738a
Annual vaccination against influenza A and B viruses is recommended in the US for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2025-2026 season are listed in Table 2.
Issue 1717 · December 9, 2024 Free
Antiviral Drugs for Seasonal Influenza for 2024-2025

Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in persons at increased risk for influenza complications (see Table 1). Updated information on…

Med Lett Drugs Ther. 2024 Dec 9; 66(1717):193-8 doi:10.58347/tml.2024.1717a
Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in persons at increased risk for influenza complications (see Table 1). Updated information on influenza activity and antiviral resistance is available from the CDC at cdc.gov/flu.
Issue 1717 · December 9, 2024 Free
Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025 (online only)

View the Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025

Med Lett Drugs Ther. 2024 Dec 9; 66(1717):e1-5 doi:10.58347/tml.2024.1717d
View the Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025
Issue 1711 · September 16, 2024 Free
Influenza Vaccine for 2024-2025

Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season are listed…

Med Lett Drugs Ther. 2024 Sep 16; 66(1711):145-50 doi:10.58347/tml.2024.1711a
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season are listed in Table 2.
Issue 1689 · November 13, 2023 Free
Antiviral Drugs for Influenza for 2023-2024

Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs…

Med Lett Drugs Ther. 2023 Nov 13; 65(1689):177-82 doi:10.58347/tml.2023.1689a
Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza for the 2023-2024 season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Issue 1689 · November 13, 2023 Free
Comparison Chart: Antiviral Drugs for Influenza for 2023-2024 (online only)

View the Comparison Chart: Antiviral Drugs for Influenza for 2023-2024

Med Lett Drugs Ther. 2023 Nov 13; 65(1689):e1-6 doi:10.58347/tml.2023.1689e
View the Comparison Chart: Antiviral Drugs for Influenza for 2023-2024
Issue 1687 · October 16, 2023 Free
Influenza Vaccine for 2023-2024

Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024 season…

Med Lett Drugs Ther. 2023 Oct 16; 65(1687):161-6 doi:10.58347/tml.2023.1687a
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024 season are listed in Table 2.
Issue 1687 · October 16, 2023 Free
Influenza Vaccine for 2023-2024

Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024 season…

Med Lett Drugs Ther. 2023 Oct 16; 65(1687):161-6 doi:10.58347/tml.2023.1687a
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024 season are listed in Table 2.
Issue 1664 · November 28, 2022 Free
Antiviral Drugs for Influenza for 2022-2023

Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1).…

Med Lett Drugs Ther. 2022 Nov 28; 64(1664):185-90
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu. None of the drugs that are FDA-approved for treatment of influenza have clinically relevant antiviral activity against SARS-CoV-2.
Issue 1664 · November 28, 2022 Free
Comparison Chart: Antiviral Drugs for Influenza for 2022-2023 (online only)

View the Comparison Chart: Antiviral Drugs for Influenza for 2022-2023

Med Lett Drugs Ther. 2022 Nov 28; 64(1664):e1-5
View the Comparison Chart: Antiviral Drugs for Influenza for 2022-2023
Issue 1660 · October 3, 2022 Free
Influenza Vaccine for 2022-2023

Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2022-2023 season…

Med Lett Drugs Ther. 2022 Oct 3; 64(1660):153-7
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2022-2023 season are listed in Table 2.
Issue 1641 · January 10, 2022 Free
Antiviral Drugs for Influenza for 2021-2022

Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at higher risk for complications (see Table 1). Antiviral…

Med Lett Drugs Ther. 2022 Jan 10; 64(1641):2-7
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at higher risk for complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Issue 1641 · January 10, 2022 Free
Comparison Chart: Antiviral Drugs for Influenza for 2021-2022 (online only)

View the Comparison Chart: Antiviral Drugs for Influenza for 2021-2022

Med Lett Drugs Ther. 2022 Jan 10; 64(1641):e1-5
View the Comparison Chart: Antiviral Drugs for Influenza for 2021-2022
Issue 1634 · October 4, 2021 Free
Influenza Vaccine for 2021-2022

Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table 2.

Med Lett Drugs Ther. 2021 Oct 4; 63(1634):153-7
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table 2.
Issue 1615 · January 11, 2021
Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza

The oral polymerase acidic endonuclease inhibitor baloxavir marboxil ( Xofluza — Genentech) is now FDAapproved for post-exposure prophylaxis of influenza in patients ≥12 years old. Baloxavir was approved…

Med Lett Drugs Ther. 2021 Jan 11; 63(1615):2-3
The oral polymerase acidic endonuclease inhibitor baloxavir marboxil ( Xofluza — Genentech) is now FDAapproved for post-exposure prophylaxis of influenza in patients ≥12 years old. Baloxavir was approved for treatment of acute uncomplicated influenza in patients ≥12 years old in 2018.1 Two neuraminidase inhibitors are FDA-approved for prophylaxis of influenza: oseltamivir (Tamiflu , and generics) in patients ≥1 year old, and zanamivir (Relenza) in patients ≥5 years old.2 Unlike oseltamivir and zanamivir, baloxavir is not FDA-approved for pre-exposure prophylaxis of influenza during institutional or community outbreaks.
Issue 1610 · November 2, 2020
Antiviral Drugs for Influenza for 2020-2021

Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1).…

Med Lett Drugs Ther. 2020 Nov 2; 62(1610):169-73
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Issue 1610 · November 2, 2020
Comparison Chart: Antiviral Drugs for Influenza (online only)

View the Comparison Chart: Antiviral Drugs for Influenza

Med Lett Drugs Ther. 2020 Nov 2; 62(1610):e176-80
View the Comparison Chart: Antiviral Drugs for Influenza
Issue 1589 · January 13, 2020
Antiviral Drugs for Influenza

Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur. FDA-approved antiviral drugs for influenza are listed in Table 2. The neuraminidase inhibitors…

Med Lett Drugs Ther. 2020 Jan 13; 62(1589):1-4
Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur. FDA-approved antiviral drugs for influenza are listed in Table 2. The neuraminidase inhibitors oseltamivir ( Tamiflu , and generics), which is taken orally, and zanamivir (Relenza) , which is inhaled, are approved for prophylaxis and treatment of acute uncomplicated influenza. The IV neuraminidase inhibitor peramivir (Rapivab) and the oral polymerase acidic (PA) endonuclease inhibitor baloxavir marboxil (Xofluza) are approved only for treatment. All of these drugs are active against both influenza A and influenza B viruses. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Issue 1589 · January 13, 2020
Expanded Table: Antiviral Drugs for Influenza (online only)

View the Expanded Table: Antiviral Drugs for Influenza

Med Lett Drugs Ther. 2020 Jan 13; 62(1589):e9-10
View the Expanded Table: Antiviral Drugs for Influenza
Issue 1563 · January 14, 2019
Antiviral Drugs for Treatment and Prophylaxis of Seasonal Influenza

Antiviral drugs can be used for treatment and prophylaxis of seasonal influenza (see Table 1). Frequently updated information on influenza activity, influenza testing, and antiviral resistance is available…

Med Lett Drugs Ther. 2019 Jan 14; 61(1563):1-4
Antiviral drugs can be used for treatment and prophylaxis of seasonal influenza (see Table 1). Frequently updated information on influenza activity, influenza testing, and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Issue 1563 · January 14, 2019
Expanded Table: Antiviral Drugs for Treatment and Prophylaxis of Seasonal Influenza 2018-2019 (online only)

View the Expanded Table: Antiviral Drugs for Seasonal Influenza

Med Lett Drugs Ther. 2019 Jan 14; 61(1563):e11-2
View the Expanded Table: Antiviral Drugs for Seasonal Influenza
Issue 1561 · December 3, 2018
Baloxavir Marboxil (Xofluza) for Treatment of Influenza

The FDA has approved baloxavir marboxil ( Xofluza – Shionogi/Genentech), the first polymerase acidic (PA) endonuclease inhibitor, for single-dose, oral treatment of acute uncomplicated influenza in patients…

Med Lett Drugs Ther. 2018 Dec 3; 60(1561):193-6
The FDA has approved baloxavir marboxil ( Xofluza – Shionogi/Genentech), the first polymerase acidic (PA) endonuclease inhibitor, for single-dose, oral treatment of acute uncomplicated influenza in patients ≥12 years old. Baloxavir is the first drug with a new mechanism of action to be approved for treatment of influenza in almost 20 years.